How much will ATAI shareholders receive?

ATAI holders are entitled to $6.75 per share in cash at closing plus one non-transferable CVR worth up to $2.50 per share if specified milestones are achieved.

What are the ATAI CVR milestones?

The CVR can pay $1.00 for VLS-01 Phase 3 initiation, $0.50 for BPL-003 U.S. approval plus DEA rescheduling, and $1.00 for VLS-01 U.S. approval plus DEA rescheduling, each within specified deadlines.

AtaiBeckley ATAI static daily chart from Finviz

Definitive merger agreement$6.75 cash at closingCVR up to $2.50Closing and milestone risk remain

AtaiBeckley $ATAI Agrees to Eli Lilly $LLY Deal: $6.75 Cash, $2.50 CVR and Potential $3.8B Value

Q: Has Lilly officially agreed to acquire AtaiBeckley?

Yes. Eli Lilly and AtaiBeckley announced a definitive merger agreement on July 16, 2026.

Q: When is the Lilly AtaiBeckley deal expected to close?

The companies expect closing in the third quarter of 2026, subject to shareholder approval, regulatory clearances and other customary conditions.

The overnight takeover report became a signed merger agreement. Lilly will pay $6.75 per ATAI share in cash at closing and issue a non-transferable contingent value right worth up to another $2.50 per share, tied to development, approval and DEA-rescheduling milestones for VLS-01 and BPL-003.

Agreement signed: July 15, 2026Announced: July 16, 2026Expected close: Q3 2026Tickers: $ATAI · $LLY

Executive summary

Eli Lilly and AtaiBeckley have entered into a definitive merger agreement. AtaiBeckley shareholders are entitled to receive $6.75 per share in cash when the transaction closes, plus one non-transferable CVR for each share that can produce up to $2.50 in additional cash if three specified BPL-003 and VLS-01 milestones are achieved within their contractual deadlines.

$6.75Cash consideration per share payable at closing

Up to $2.50Additional contingent cash through one CVR per share

~$2.8BAggregate upfront equity value stated by Lilly and AtaiBeckley

Up to ~$3.8BPotential aggregate equity value if every CVR milestone is paid

The transaction is not subject to a financing condition. Both boards approved it, and Apeiron Investment Group together with all AtaiBeckley directors and officers signed voting and support agreements covering approximately 15% of the outstanding common stock. Closing remains subject to approval by AtaiBeckley shareholders, regulatory clearances and other customary conditions.

The most important valuation distinction

The guaranteed contractual value is not $9.25 today. The fixed closing payment is $6.75 per share, subject to the merger closing. The additional $2.50 is contingent, split across three milestones, may take several years to resolve and may never be paid. The CVR is not expected to trade on an exchange and is transferable only in limited circumstances.

Definitive deal terms: what ATAI holders are being offered

The merger agreement was signed on July 15 among AtaiBeckley, Eli Lilly and Albali Acquisition Corporation, an indirect wholly owned Lilly subsidiary. Albali will merge into AtaiBeckley, and AtaiBeckley will survive as a wholly owned Lilly subsidiary.

Term	Confirmed detail	Investor interpretation
Cash at closing	$6.75 per ATAI share, without interest and subject to applicable withholding	This is the fixed merger consideration if the transaction closes.
CVR	One non-transferable CVR per share, worth up to $2.50 in aggregate	Contingent value depends on three development and regulatory milestones.
Upfront equity value	Approximately $2.8 billion	Company-stated aggregate value of the $6.75 cash component.
Potential CVR value	Approximately $1.0 billion in aggregate	No assurance that any CVR payment will be earned.
Potential maximum value	Approximately $3.8 billion, or $9.25 per share	Only if the merger closes and all three milestones are achieved on time.
Premium	Approximately 40% to the 30-day VWAP ended July 15	The quoted premium applies to the $6.75 closing payment, not the maximum CVR value.
Expected closing	Third quarter of 2026	Subject to shareholder approval, regulatory clearance and customary conditions.
Financing condition	None	Lilly is not relying on external deal financing as a closing condition.
Voting support	Approximately 15% of outstanding shares	Apeiron, directors and officers agreed to vote for the transaction, subject to the agreements.

The agreement changes the analytical framework completely. Before the announcement, the stock represented a standalone clinical-stage company plus an uncertain takeover probability. After signing, the main near-term equity questions become whether the merger closes, how long closing takes and how the market values the three CVR milestones.

The $2.50 CVR: three milestones, three deadlines and three distinct risks

Each share outstanding at closing receives one CVR. The CVR does not represent Lilly stock, ownership in AtaiBeckley or voting rights. It will not be registered as a publicly traded security and will be transferable only in limited circumstances. Each milestone is evaluated independently.

Potential payment	Milestone	Deadline	Main risk
$1.00 per CVR	Initiation of a Phase 3 clinical trial of VLS-01	Before the fourth anniversary of closing	Phase 2b data, FDA alignment, program prioritization and trial readiness must support Phase 3 initiation.
$0.50 per CVR	U.S. regulatory approval and DEA rescheduling of BPL-003	Before the fifth anniversary of closing	Phase 3 success, BLA/NDA review, manufacturing, benefit-risk and controlled-substance scheduling all matter.
$1.00 per CVR	U.S. regulatory approval and DEA rescheduling of VLS-01	Before the seventh anniversary of closing	VLS-01 must first advance through Phase 3, filing, approval and DEA rescheduling within the deadline.

The easiest milestone is not risk-free

The VLS-01 Phase 3 initiation milestone may appear easier than approval, but it still depends on the Phase 2b Elumina results, Lilly’s interpretation of the data, FDA feedback, manufacturing readiness and a decision to invest in the program. The contractual milestone is initiation of a Phase 3 trial, not simply preparation, protocol submission or public guidance.

Approval alone is insufficient for two milestones

The BPL-003 and VLS-01 regulatory milestones require both U.S. regulatory approval and DEA rescheduling. Psychedelic-derived therapies can receive FDA approval while still requiring a scheduling process before ordinary commercial distribution. The milestone wording therefore creates two gates rather than one.

CVRs are not cash equivalents

A holder should not automatically value the CVR at $2.50. A reasonable valuation must discount each payment for clinical probability, regulatory probability, DEA timing, milestone deadline, time value and the possibility of disputes over whether a milestone was achieved under the contractual definition.

Merger mechanics, closing conditions and termination risk

The merger requires approval from holders of at least a majority of AtaiBeckley’s outstanding common shares. The parties also need applicable antitrust and other regulatory clearances, and no law or final order may prohibit the transaction. Lilly’s obligation also depends on the accuracy of AtaiBeckley’s representations, compliance with covenants and the absence of a continuing company material adverse effect.

Outside date

The initial outside date is six months after the merger agreement. It automatically extends to nine months if specified antitrust or foreign-investment conditions remain outstanding. This does not mean management expects closing to take that long; the public target remains Q3 2026. The outside date defines contractual termination rights if closing is delayed.

No-shop, superior proposals and the termination fee

AtaiBeckley is subject to customary no-shop restrictions. The board may engage with an unsolicited proposal that it determines constitutes or could reasonably lead to a superior proposal, and Lilly receives customary matching rights. If AtaiBeckley terminates to accept a superior proposal, or if Lilly terminates after a qualifying change in the board’s recommendation, AtaiBeckley must pay Lilly a $104.3 million termination fee. A similar tail fee can apply if a competing proposal appears before certain terminations and a qualifying alternative transaction occurs within twelve months.

No stated reverse termination fee in the 8-K summary

The filed 8-K summary describes specific performance rights and the AtaiBeckley termination fee. It does not identify a conventional reverse termination fee payable by Lilly in the principal-term summary. Investors should review the full merger agreement and later proxy for the complete allocation of closing and enforcement risk.

Completion risk is lower than rumor risk, but it is not zero

The signed agreement, unanimous board approvals, lack of a financing condition and 15% voting support materially strengthen completion probability. Shareholder rejection, regulatory delay, litigation, a material-adverse-effect dispute or a superior proposal can still alter the outcome.

Timeline: from after-hours takeover report to signed merger

November 2025

Atai completed its combination with Beckley Psytech, bringing BPL-003 into a more concentrated late-stage mental-health platform.

July 6, 2026

AtaiBeckley announced that the final patient had been dosed in the 156-patient VLS-01 Phase 2b Elumina study and retained Q4 2026 topline guidance.

July 15, 2026 — after hours

Bloomberg reported acquisition talks and Reuters relayed the report, producing a sharp after-hours repricing while official terms remained unknown.

July 15, 2026 — agreement date

AtaiBeckley, Lilly and Albali Acquisition Corporation signed the merger agreement.

July 16, 2026

The companies publicly announced the definitive transaction and AtaiBeckley filed the 8-K, merger agreement, support-agreement form and joint press release.

Q3 2026 target

The parties expect closing, subject to the shareholder vote, regulatory clearances and other closing conditions.

Why Lilly is buying AtaiBeckley

Lilly’s stated rationale centers on expanding its neuroscience pipeline into difficult mental-health conditions and accelerating a platform of rapid-acting neuroplastogens. The acquisition is not simply a bet on the word “psychedelic.” It is a purchase of late-stage assets, formulations, intellectual property, clinical-development infrastructure and a potential shorter-duration interventional-psychiatry model.

BPL-003 creates a Phase 3 anchor

BPL-003 is an intranasal formulation of mebufotenin benzoate, a synthetic form of 5-MeO-DMT, in Phase 3 development for treatment-resistant depression. FDA Breakthrough Therapy designation and a roughly two-hour average in-clinic visit distinguish it from longer-session psychedelic approaches.

VLS-01 adds a near-term option

The Phase 2b Elumina readout is expected in Q4 2026. Lilly acquires the upside if the trial succeeds, while the CVR structure shifts part of the future value back to former ATAI holders only if development progresses.

Operational scalability matters

Both lead programs are designed around shorter supervised treatment windows. If efficacy and durability hold, shorter sessions could improve clinic throughput, staffing economics and payer feasibility relative to therapies requiring substantially longer monitoring.

Lilly brings development scale

Lilly can provide clinical operations, regulatory expertise, manufacturing investment, neuroscience-commercial infrastructure and financial capacity that a standalone AtaiBeckley would have had to build or finance over time.

BPL-003: the lead asset and the $0.50 approval CVR milestone

BPL-003 is a proprietary intranasal mebufotenin-benzoate formulation being developed for treatment-resistant depression. AtaiBeckley describes it as capable of generating rapid and durable reductions in depressive symptoms after an in-clinic visit lasting approximately two hours on average. Lilly specifically identified BPL-003 as the lead program in the acquisition announcement.

Phase 3 program

The ReConnection pivotal program includes two studies expected to enroll approximately 350 and 230 patients. Both use change in MADRS score at Week 4 as a principal efficacy measure and include long-term extension components. The development strategy must prove that the rapid signal seen in earlier studies can be reproduced under controlled, multicenter conditions with acceptable acute and longer-term safety.

What the CVR requires

The BPL-003 CVR payment is $0.50 per share, contingent on U.S. regulatory approval and DEA rescheduling before the fifth anniversary of closing. A successful Phase 3 study alone does not trigger payment. Filing acceptance alone does not trigger payment. FDA approval without completed DEA rescheduling does not trigger payment under the stated milestone.

Strategic upside

Late-stage entry into treatment-resistant depression.
Breakthrough Therapy designation.
Potentially practical two-hour treatment workflow.
Durable-effect hypothesis that could reduce treatment frequency.
Lilly resources may accelerate development, manufacturing and commercialization preparation.

Remaining risk

Phase 3 efficacy and safety remain unproven.
Functional unblinding and expectancy effects remain methodological issues.
Clinic capacity and reimbursement are not yet established.
Controlled-substance manufacturing, storage and DEA rescheduling add complexity.
The five-year CVR deadline can expire without payment.

VLS-01: the asset behind $2.00 of the potential $2.50 CVR

VLS-01 is a proprietary buccal oral-transmucosal DMT film in the 156-patient Phase 2b Elumina study for treatment-resistant depression. Topline data remain expected in Q4 2026. VLS-01 accounts for two separate CVR payments: $1.00 for Phase 3 initiation and another $1.00 for U.S. approval plus DEA rescheduling.

Element	Current status	Why it matters
Phase 2b enrollment	156 randomized patients; last patient dosed	Creates a defined Q4 2026 data catalyst under Lilly ownership if the merger closes first.
Primary endpoint	VLS-01 versus placebo change in MADRS at Day 29	Placebo-adjusted effect, confidence intervals and consistency will determine whether Phase 3 is justified.
First CVR milestone	Phase 3 initiation before fourth closing anniversary	Worth $1.00 per CVR.
Second CVR milestone	U.S. approval plus DEA rescheduling before seventh closing anniversary	Worth another $1.00 per CVR.

The Phase 2b result remains one of the most important scientific events in the whole transaction. Positive data could make the first VLS-01 milestone more plausible and increase the probability-adjusted value of the second. Negative, inconsistent or safety-limited results could reduce both milestones toward zero.

What to examine in the data

Placebo-adjusted MADRS effect and confidence intervals.
Response and remission rates at Day 29 and later visits.
Site-level consistency and sensitivity analyses.
Discontinuations, missing data and protocol deviations.
Cardiovascular, psychiatric and dissociative events.
Suicidality monitoring and C-SSRS results.
Whether durability supports a practical retreatment interval.

EMP-01 and discovery assets: optionality beyond the main CVR

EMP-01 is an oral R-MDMA program in Phase 2 development for social anxiety disorder. AtaiBeckley reported exploratory evidence consistent with potential clinical activity, but EMP-01 is not tied to a separately disclosed CVR milestone. Its value transfers to Lilly within the acquisition price.

The discovery portfolio includes novel 5-HT2A agonists and non-hallucinogenic neuroplastogen concepts. These assets remain early, but they give Lilly a research platform beyond BPL-003 and VLS-01. The scientific question is whether neuroplastic or therapeutic benefits can be separated from a strong hallucinogenic experience while retaining meaningful efficacy.

Cash, burn, equity awards and warrants

AtaiBeckley reported $209.9 million in cash, cash equivalents and short-term securities at March 31, 2026 and had guided standalone runway into 2029. Under the signed transaction, that cash and the company’s future development obligations become part of the acquired business if the merger closes. Public ATAI holders will no longer bear standalone financing risk after closing; they will instead receive the cash consideration and retain only the contractual CVR exposure.

Stock options

Options with exercise prices below $6.75 will be cashed out for the spread between $6.75 and the exercise price and will receive one CVR for each underlying share, without regard to vesting. Options with exercise prices equal to or above $6.75 will be cancelled for no consideration.

Restricted stock units

Outstanding unvested, or vested but unsettled, RSUs will be cancelled in exchange for $6.75 cash per underlying share plus one CVR per underlying share, subject to withholding.

Pre-funded warrants

Pre-funded warrants remain outstanding after the effective time and become exercisable for the same merger consideration that the holder would have received had the warrant been fully exercised immediately before closing. This is important because simple common-share calculations can understate the fully diluted purchase cost.

How to value and trade ATAI after the agreement

Once a definitive cash-and-CVR merger is signed, the stock should be analyzed as an event-driven security rather than a conventional standalone biotech. The fixed $6.75 consideration creates the principal closing-value anchor. The trading price can remain below $6.75 because of time to closing, regulatory and shareholder-vote risk, taxes, opportunity cost and the possibility that the agreement terminates.

The stock may also trade above $6.75 because the market assigns present value to the CVR. The amount above $6.75 should not automatically be interpreted as irrational. It represents a market estimate of the probability-adjusted, time-discounted value of the three contingent payments, plus or minus technical factors.

Observed price component	What it may represent	Main risk
Below $6.75	Closing discount and time value	Deal delay, vote risk, regulatory risk or termination probability.
Between $6.75 and $7.75	Some value assigned to the VLS-01 Phase 3 milestone and/or other CVR events	Market may overestimate data quality or Lilly’s willingness to advance VLS-01.
Near $9.25	Very high confidence that all three CVR milestones will pay	This would ignore years of clinical, approval, DEA and deadline risk unless heavily discounted elsewhere.

There is now a real deal spread—but not a simple one

The cash spread can be calculated against $6.75. The CVR spread cannot be treated as a fixed merger payment. Any event-driven valuation should show the cash component separately from the probability-weighted milestone component.

Recent insider sales: context remains important, accusations remain unsupported

Recent Form 4 filings showed option exercises and sales by several AtaiBeckley insiders before the public takeover report. The filings stated that the transactions were executed under Rule 10b5-1 trading plans adopted months earlier. The merger announcement does not retroactively establish improper trading.

Insider	Transaction	Filed context
Robert Hershberg	Exercised options and sold 100,000 shares on July 7	10b5-1 plan adopted April 7, 2026.
Gerd Kochendoerfer	Exercised options and sold 50,000 shares on June 26	10b5-1 plan adopted March 27, 2026.
Kevin Craig	Exercised options and sold 42,579 shares on June 25	10b5-1 plan adopted December 19, 2025.

The responsible conclusion remains unchanged: the transactions are relevant capital-structure history, but the reviewed filings do not prove that the sellers knew about the merger talks when the plans were adopted or that the trades were based on material nonpublic information.

What the Lilly deal means for psychedelic and rapid-acting psychiatry stocks

A signed acquisition by one of the world’s largest pharmaceutical companies is a stronger sector signal than a rumor. It validates that late-stage psychedelic-derived and neuroplastogen assets can become strategic M&A targets before FDA approval. The read-through is most relevant for public developers such as $CMPS, $GHRS, $CYBN and $MNMD, but the comparison must remain asset-specific.

Positive read-through

Large pharma willingness to buy before approval.
Strategic value assigned to shorter-duration clinic models.
More attention to differentiated formulations and composition-of-matter IP.
Potentially stronger partnering leverage across the sector.

Why sympathy trades may fade

Lilly may value BPL-003 and VLS-01 specifically rather than the whole sector.
Clinical stages, session duration and trial quality differ.
Peers may require more financing before pivotal data.
The AtaiBeckley deal uses a large contingent component, showing that risk remains.

The CVR structure itself is informative. Lilly is willing to pay a substantial upfront amount, but approximately $1 billion of additional value is tied to development and approval milestones. That is both validation and discipline: the buyer values the platform while refusing to pay the full potential value before key risks are resolved.

Completion and CVR scenarios

High-value outcome

The merger closes in Q3, VLS-01 produces supportive Phase 2b data and enters Phase 3, BPL-003 succeeds in Phase 3 and reaches approval plus DEA rescheduling, and VLS-01 later does the same. Former holders receive the full $9.25 per-share nominal value over time.

Mixed outcome

The merger closes and Lilly initiates VLS-01 Phase 3, paying the first $1.00, but one or both approval milestones fail, miss their deadlines or remain unresolved. Total realized value falls between $6.75 and $9.25.

Low-value outcome

The merger closes but no CVR milestone is paid, leaving holders with $6.75. A separate deal-failure scenario remains possible before closing and could return ATAI to a standalone clinical-stage valuation.

Frequently asked questions

Has Lilly officially agreed to acquire AtaiBeckley?

Yes. The companies announced a definitive merger agreement on July 16, 2026, signed July 15.

How much cash will ATAI shareholders receive?

$6.75 per share in cash if the merger closes, without interest and subject to applicable withholding.

Is the deal worth $9.25 per share?

$9.25 is the maximum nominal value: $6.75 cash plus up to $2.50 through the CVR. The CVR payments are not guaranteed.

What triggers the CVR payments?

$1.00 for VLS-01 Phase 3 initiation before the fourth closing anniversary; $0.50 for BPL-003 U.S. approval plus DEA rescheduling before the fifth anniversary; and $1.00 for VLS-01 U.S. approval plus DEA rescheduling before the seventh anniversary.

Can the CVR be traded?

It will not be listed or registered as a tradable security and is transferable only in limited circumstances.

When is the acquisition expected to close?

The companies target the third quarter of 2026, subject to shareholder approval, regulatory clearances and other conditions.

Could another bidder emerge?

An unsolicited superior proposal remains legally possible under the merger agreement, subject to no-shop provisions, Lilly matching rights and a $104.3 million termination fee in specified circumstances.

What happens if the deal fails?

ATAI would remain a standalone clinical-stage biotechnology company, and the share price could reprice sharply based on BPL-003, VLS-01, cash runway and financing expectations.

Merlintrader bottom line

The story is no longer “Lilly may buy AtaiBeckley.” Lilly and AtaiBeckley have signed a definitive agreement. The fixed economic component is $6.75 per share in cash at closing. The remaining potential value is a carefully structured CVR worth up to $2.50 per share, with most of that value tied to VLS-01 and all approval payments requiring both FDA approval and DEA rescheduling.

The structure tells investors what Lilly believes and what it is unwilling to underwrite upfront. Lilly is paying approximately $2.8 billion now for the pipeline, organization and strategic position. It is offering up to another $1 billion only if development advances and key regulatory events occur. That makes the acquisition an important validation of rapid-acting neuroplastogen psychiatry, but not a declaration that the clinical risks have disappeared.

For ATAI holders, the correct framework now has three layers: closing probability, the $6.75 cash spread and the probability-adjusted value of each CVR milestone. BPL-003 remains the lead program, but VLS-01 controls $2.00 of the potential $2.50 CVR and therefore becomes unusually important to former shareholders even after Lilly takes control.

One-sentence conclusion

Lilly has converted the ATAI takeover rumor into a signed $6.75-cash merger with up to $2.50 of milestone value, shifting the debate from whether a buyer exists to whether the transaction closes and how much of the CVR will ever be earned.